Alternative explanations for development of late-onset neutropenia in rituximab-treated rheumatic disease patients: comment on the article by Tesfa et al.
Emilio
E
Besada
D058846:Antibodies, Monoclonal, Murine-Derived / Q000009:adverse effects*; D018501:Antirheumatic Agents / Q000009:adverse effects*; D001402:B-Lymphocytes; D006801:Humans; D009503:Neutropenia / Q000139:chemically induced*; D012216:Rheumatic Diseases / Q000188:drug therapy*
D058846:Antibodies, Monoclonal, Murine-Derived; D018501:Antirheumatic Agents